ClinicalTrials.gg
CompletedNCT06812780CAMPOLINAUpdated Sep 24, 2025

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389

A Phase 1 interventional study of AZD2389 in Hepatic Impairment, sponsored by AstraZeneca. Completed at 5 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Lymphoma, Follicular by AstraZeneca — 4 open to participants now, 6 under way, 1 of them phase 3. Lymphoma, Follicular · AstraZeneca.

Enrollment
10th of 16
35 · median 130
Started
2025
with 1 other
Phase 1
7 of 17
1 open now
Registered
15th of 17
by date

Among the 17 studies in Lymphoma, Follicular by AstraZeneca, this one is the 10th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 in phase 1, and was the 15th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

4 of the 17 studies in Lymphoma, Follicular by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Lymphoma, Follicular by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to examine the safety and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.

Read the detailed description

This is a single-dose, non-randomised, open-label, parallel-group study to examine the PK, fibroblast activation protein activity, safety, and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.

The study is planned to consist of:

  • Cohort 1: Participants with normal hepatic function (sex-, age-, and body mass index [BMI]-matched)
  • Cohort 2: Participants with mild hepatic impairment (CP A classification)
  • Cohort 3: Participants with moderate hepatic impairment (CP B classification)
  • Cohort 4 (Optional): Participants with severe hepatic impairment (CP C classification)

Safety, tolerability, and available plasma PK data up to 48 hours post-dose from at least 4 participants in each of the mild hepatic impairment (CP Class A) and moderate hepatic impairment (CP Class B) cohorts must have been assessed by the investigator(s), medical monitor, and sponsor prior to the decision to proceed with evaluation/recruitment of participants with severe hepatic impairment (CP Class C). Cohort 1 (normal hepatic function) will be initiated in parallel with Cohorts 2 and 3.

03

Conditions studied

  • Hepatic Impairment

Keywords

  • Mild
  • Moderate
  • Severe
  • Matched Healthy Controls
  • Liver Fibrosis
  • Liver Cirrhosis
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Hepatic:

  • Participant with a diagnosis of stable hepatic impairment

For Healthy:

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests.

All participants:

- Body weight ≥ 50 kg; within the range of 18.0 to 42.0 kg/m2 (inclusive).

Exclusion criteria

Exclusion Criteria:

  • Participant has \< 60 mL/minute/1.73 m2
  • Positive test for at screening
  • History of severe allergy/ or ongoing allergy/hypersensitivity
  • History of severe dermatological disorders
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants with normal hepatic function (sex-, age-, and body mass index \[BMI\]-matched)

    Drug: AZD2389

  • Experimental
    Cohort 2

    Participants with mild hepatic impairment (CP A classification)

    Drug: AZD2389

  • Experimental
    Cohort 3

    Participants with moderate hepatic impairment (CP B classification)

    Drug: AZD2389

  • Experimental
    Cohort 4

    Participants with severe hepatic impairment (CP C classification)

    Drug: AZD2389

Interventions

  • Single oral dose of AZD2389 in participants from all cohorts

06

What researchers measure

Primary outcomes

  1. Plasma PK parameter Cmax

    maximum observed plasma concentration

    Time frame: pre-dose to 48 hours post-dose

  2. Plasma PK parameter AUCinf

    area under the concentration-time curve from zero to infinity

    Time frame: pre-dose to 48 hours post-dose

  3. Plasma PK parameter AUClast

    area under the concentration-time curve from zero to the last measurable concentration

    Time frame: pre-dose to 48 hours post-dose

Secondary outcomes

  1. Plasma PK parameter t1/2λz

    half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve

    Time frame: pre-dose to 48 hours post-dose

  2. Plasma PK parameter Tmax

    time to reach maximum observed plasma concentration

    Time frame: pre-dose to 48 hours post-dose

  3. Plasma PK parameter CL/F

    apparent total body clearance of drug from plasma after extravascular administration

    Time frame: pre-dose to 48 hours post-dose

  4. Plasma PK parameter Vz/F

    apparent volume of distribution during the terminal phase after extravascular administration.

    Time frame: pre-dose to 48 hours post-dose

  5. Urine PK parameter Ae(t1-t2)

    cumulative amount of unchanged drug excreted into the urine for the interval between time 1 and time 2

    Time frame: pre-dose to 48 hours post-dose

  6. Urine PK parameter CLr

    renal clearance of the drug from plasma

    Time frame: pre-dose to 48 hours post-dose

  7. Urine PK parameters fe(t1-t2)

    fraction of the drug excreted into the urine for the interval between time 1 and time 2

    Time frame: pre-dose to 48 hours post-dose

07

Study locations

5 sites
  • Research Site
    Chandler, Arizona 85225, United States
  • Research Site
    Rialto, California 92377, United States
  • Research Site
    Miami Lakes, Florida 33014, United States
  • Research Site
    Orlando, Florida 32809, United States
  • Research Site
    San Antonio, Texas 78215, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Sep 2025, 7 months.

Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Follicular, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 71. This study's 7 months is below that.

Counting every sponsor, half of 173 studies reached it within 51 months; a quarter within 30 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2025
First posted
Feb 6, 2025
StartActual
Feb 4, 2025
Primary completionActual
Sep 4, 2025
CompletionActual
Sep 4, 2025
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06812780
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 6, 2025
Start date
Feb 4, 2025
Primary completion
Sep 4, 2025
Completion
Sep 4, 2025
Last update
Sep 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD2389

Start the discussion